SABSW
SAB Biotherapeutics IncNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
0.09
EPS
$0.29
Beta
0.61
52W High
$0.06
52W Low
$0.02
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 114,700 |
| Gross Profit (TTM) | $-33.35M |
| EBITDA | $-45.87M |
| Operating Margin | 0.00% |
| Return on Equity | 15.00% |
| Return on Assets | -28.20% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $3.18 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -62.40% |
| Shares Outstanding | 0 |
| Float | $34.88M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/9/2026